

New Hampshire Medicaid Fee-for-Service Program Stromectol® (ivermectin) Criteria

Approval Date: June 29, 2023

Pharmacology

Ivermectin is a broad-spectrum antiparasitic agent that is used to treat onchocerciasis, helminthiases, and scabies. In response to coronavirus disease 2019 (COVID-19), unsubstantiated prescribing of ivermectin in high doses has occurred across the US. Per National Institutes of Health (NIH) guidance, there is insufficient evidence to recommend ivermectin for the treatment of COVID-19 until well-designed, adequately powered, and well-conducted clinical trials are completed to establish efficacy.

Medication

| Brand Name | Generic Name | Dosage Strengths |
|-------------|--------------|------------------|
| Stromectol® | ivermectin | 3 mg tablets |

Criteria for Approval

- 1. Diagnosis of a parasitic infection; OR
- 2. Diagnosis of scabies with failure of at least one topical treatment:
 - a. Permethrin cream 5%
 - b. Crotamiton lotion or cream 10%
 - c. Sulfur ointment 5-10%
 - d. Lindane lotion 1%; AND
- 3. Length of therapy for up to 1 month with a maximum of 10 tablets.

Criteria for Denial

1. Prior approval will be denied if the approval criteria are not met

Length of Authorization: 1 month

References

Available upon request.

Revision History

| Reviewed by | Reason for Review | Date Approved |
|-----------------------|-------------------|---------------|
| DUR Board | New | 12/02/2021 |
| Commissioner Designee | New | 01/14/2022 |
| DUR Board | Review | 06/19/2023 |
| Commissioner Designee | Revision | 06/29/2023 |